U.S. Office REITs Stock News

We wouldn't blame MoonLake Immunotherapeutics ( NASDAQ:MLTX ) shareholders if they were a little worried about the fact...

If you are wondering whether Astronics at US$76.26 still offers value after a big run, the starting point is understanding what the current price actually reflects about the business. The stock has recorded returns of 4.7% over the last 7 days, 11.0% over 30 days, 34.7% year to date and 234.6% over the past year, with 3 year and 5 year returns of 379.6% and 342.9% respectively. This naturally raises questions about how much optimism is already priced in. Recent coverage around Astronics has...

On 7 April 2026, Alloy Therapeutics announced a collaboration and license agreement granting Biogen access to its proprietary AntiClastic antisense oligonucleotide (ASO) platform to develop antisense therapeutics against multiple undisclosed RNA targets, with Alloy receiving an upfront payment plus potential milestones and tiered royalties. A key angle for investors is that this deal pairs Biogen’s neurological drug development expertise with a next-generation ASO platform specifically...

Sirius XM Holdings recently reported its latest quarterly results, with revenue remaining flat year on year while earnings per share slightly exceeded analyst expectations despite a miss on adjusted operating income. This mix of stable revenue and better-than-expected profitability has drawn attention to how effectively Sirius XM is managing costs and monetization in a highly competitive audio market. We’ll now examine how this earnings-per-share beat, despite flat revenue and an adjusted...

Amkor Technology (AMKR) is back on traders’ screens after a strong earnings release, with revenue, EPS, and adjusted operating income all ahead of analyst estimates and the share price reacting sharply. See our latest analysis for Amkor Technology. The stock’s strong earnings beat follows a powerful run, with a 30 day share price return of 33.81% and a 1 year total shareholder return of about 3.7x, suggesting momentum is still firmly building around Amkor Technology. If this kind of move has...

United Therapeutics recently announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to miroliverELAP, its investigational external liver assist device developed by Miromatrix to provide temporary support for acute liver failure patients using a bioengineered liver derived from decellularized porcine scaffolds and human donor cells. This RMAT designation, combined with earlier positive Phase 1 data for miroliverELAP and progress across United Therapeutics’...

What NiSource’s Recent Returns Tell You NiSource (NI) has drawn attention after a period where the stock showed a 0.3% gain over the past day, a 1.5% decline over the past week, and mixed performance over the month and past 3 months. See our latest analysis for NiSource. At a share price of US$47.37, NiSource shows a 90 day share price return of 8.8% and a year to date gain of 12.4%, while the 1 year total shareholder return of 25.0% points to momentum that has built over a longer period. If...

AerCap Holdings appointed Doug Parker as a Non Executive Director to its board, bringing in a former airline industry leader. The change follows the latest AGM, which included the retirement of Julian (Brad) Branch and the re appointment of several other directors. The moves indicate ongoing board refresh at NYSE:AER that could influence future oversight and decision making. AerCap Holdings, trading on the NYSE under ticker NYSE:AER, last closed at $147.24. The stock shows a 56.3% return...

For readers wondering whether First Solar at around US$195 has already run its course or still offers value, this article walks through what the current price might be implying about the stock. The share price has pulled back around 2.8% over the last week and 2.1% over the last month, but still reflects a 56.9% return over the past year and 133.4% over five years, alongside a 28.8% decline year to date and a 10.5% decline over three years. Recent headlines have focused on broad interest in...

Why recent results matter for Ross Stores (ROST) Ross Stores (ROST) has been in focus after strong quarterly results, steady same store sales growth, and a high return on invested capital, all of which have shaped a more positive tone among investors. See our latest analysis for Ross Stores. Ross Stores’ share price has shown firm upward momentum, with a 30 day share price return of 7.79% and a 1 year total shareholder return of 63.24%, indicating strong recent and longer term interest in the...

If you are wondering whether Prudential Financial's current share price reflects its true worth, starting with a clear look at valuation can help you decide how it fits in your portfolio. The stock last closed at US$99.42, with returns of 2.9% over 7 days, 6.7% over 30 days, a negative 12.7% year to date, 6.2% over 1 year, 31.5% over 3 years, and 29.1% over 5 years, giving you a mixed picture of recent and longer term performance. Recent moves in Prudential Financial's share price sit...

Why Expedia Group Is On Investors’ Radar Today Expedia Group (EXPE) is back on watchlists after recent share price moves, with the stock up over the past week and month but showing a negative return across the past 3 months and year to date. See our latest analysis for Expedia Group. This recent 1-day share price return of 3.57% and 7-day share price return of 8.67% sit against a weaker 90-day share price return of a 12.52% decline. The 1-year total shareholder return of 70.11% highlights how...

If you are wondering whether Intuitive Surgical at around US$468 per share is offering fair value or asking too much, this breakdown is designed to help you frame that question clearly. The stock has returned 1.3% over the last week, while the 30 day return sits at a 3.1% decline and the year to date return at a 16.7% decline, with the one year return at a 2.7% decline despite a 56.9% three year return and a 57.6% five year return. Recent attention on Intuitive Surgical has focused on its...

Wondering if Coca-Cola at around US$75.31 is fairly priced, expensive, or still offering value? This article breaks down what the current market tag might really mean for you. The stock is showing mixed recent returns, with a 2.6% decline over 7 days and a 3.2% decline over 30 days, alongside a 9.0% return year to date and 8.1% over the last year. These moves are playing out against a backdrop of ongoing attention on large, established consumer brands. Investors regularly reassess how much...

In April 2026, Stifel upgraded Texas Instruments after its March 5 announcement of a collaboration where Nvidia and Texas Instruments will combine AI compute with TI’s real-time control, sensing, and power technologies to advance humanoid robotics and AI applications. This partnership highlights how Texas Instruments’ analog and embedded chips may become more embedded in emerging AI and robotics ecosystems across data centers and edge devices. We’ll now examine how Texas Instruments’...

WaterBridge Infrastructure (WBI) has recently drawn investor attention after its latest reported figures showed annual revenue of US$525.553 million alongside a net income loss of US$4.537 million, prompting closer scrutiny of its water management business model. See our latest analysis for WaterBridge Infrastructure. The recent annual loss has not stopped momentum in the share price, with WaterBridge Infrastructure posting a 1 day share price return of 2.44% and a year to date share price...

This article examines whether Avantor's current share price reflects its underlying value, or if the market may be undervaluing or overvaluing the company, by focusing on what the numbers indicate about value. Avantor last closed at US$8.37, with a 4.6% return over the past week and 10.0% over the past month. The year to date return is a 27.0% decline and the 1 year return is a 45.1% decline, extending to a 59.5% decline over 3 years and a 74.0% decline over 5 years. These moves come against...

Investors may be wondering whether Essential Properties Realty Trust is attractively priced at its current level, or if the recent run has already reflected the available good news. The stock last closed at US$32.67, with returns of 3.1% over 7 days, a 1% decline over 30 days, 8.7% year to date, 6.7% over 1 year, 52.0% over 3 years, and 56.1% over 5 years. These moves are occurring alongside an ongoing flow of company and sector updates that continue to reshape how investors view...

Event driven snapshot of Synchrony Financial (SYF) Synchrony Financial (SYF) has attracted fresh attention after recent share price moves, with the stock showing a 0.6% return over the past day and an 18.7% gain over the past month. See our latest analysis for Synchrony Financial. The recent 18.7% 1 month share price return comes after a weaker start to the year, with the year to date share price return at a 10.23% decline. At the same time, the 1 year total shareholder return of 65.47% and 3...

Atkore (ATKR) is back on investors’ radar after recent share moves, with the stock up around 21% over the past month but down about 4% over the past 3 months. See our latest analysis for Atkore. That recent 20.5% 1 month share price return contrasts with a 4.5% 3 month share price decline and a 19.7% 1 year total shareholder return, suggesting momentum has picked up again after a weaker stretch. If Atkore’s rebound has your attention and you want to see what else is moving around power...

Wondering whether Honeywell International at around US$232.19 is priced for opportunity or already reflects much of its quality is a fair question for any investor looking at the stock today. The share price has been relatively steady in the near term, with a 0.1% decline over the last 7 days and a 1.0% decline over the last 30 days, while still showing an 18.5% return year to date and 30.2% over the past year. Recent coverage has focused on Honeywell International as a long term industrial...

Mama's Creations (MAMA) just closed FY 2026 with fourth quarter revenue of US$54.0 million and EPS of US$0.05, capping a year where trailing 12 month revenue reached US$171.7 million and EPS came in at US$0.14. The company has seen quarterly revenue move from US$33.6 million in Q4 FY 2025 to US$54.0 million in Q4 FY 2026, alongside EPS shifting from US$0.04 to US$0.05 over the same period. This is setting up a results season in which investors are closely watching how efficiently that revenue...

Wondering whether Voyager Technologies at around US$29.91 is offering fair value or a potential mismatch between price and worth? This breakdown is designed to help you frame that question clearly. The stock has recently posted returns of 6.4% over the last week, 9.0% over the last month, and 7.7% year to date. These figures may be catching the eye of investors watching for changing expectations or risk perceptions. Recent coverage has focused on Voyager Technologies as part of ongoing...

If you are wondering whether Zimmer Biomet Holdings at around US$94.20 offers good value today, the key is understanding what the current price actually reflects. The stock has returned 1.3% over the last 7 days, 1.0% over the last 30 days, 4.6% year to date and shows a 1.8% decline over the last year, alongside deeper 3 year and 5 year declines of 29.9% and 42.7%. These mixed returns come as the company continues to attract attention for its position in orthopedics and related medical...